专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09428508B2 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors 有权
标题翻译： 2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，为FAK / Pyk2抑制剂
公开(公告)号：US09428508B2
公开(公告)日：2016-08-30
申请号：US13978475
申请日：2012-01-07
申请人： Dengming Xiao , Liang Cheng , Xijie Liu , Yuandong Hu , Xinhe Xu , Zhihua Liu , Lipeng Zhang , Wei Wu , Shulong Wang , Yu Shen , Gen Li , Yin Wang , Sheng Zhao , Chonglong Li , Jia Tang , Honghao Yu
发明人： Dengming Xiao , Liang Cheng , Xijie Liu , Yuandong Hu , Xinhe Xu , Zhihua Liu , Lipeng Zhang , Wei Wu , Shulong Wang , Yu Shen , Gen Li , Yin Wang , Sheng Zhao , Chonglong Li , Jia Tang , Honghao Yu
IPC分类号： C07D487/04 , C07D413/12 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/4523 , A61P35/00 , C07D401/12 , C07D493/12 , C07D417/12
CPC分类号： C07D487/04 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D401/12 , C07D413/12 , C07D417/12 , C07D493/12
摘要： The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
摘要翻译：本发明涉及一种新型的作为FAK和/或Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，其制备方法和组合物以及该化合物用于抑制FAK和/或Pyk2的方法和用于治疗FAK和/或Pyk2介导的病症或疾病的方法。

2. 发明申请

US20130281438A1 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS 有权
标题翻译： 2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，以FAK / Pyk2抑制剂
公开(公告)号：US20130281438A1
公开(公告)日：2013-10-24
申请号：US13978475
申请日：2012-01-07
申请人： Dengming Xiao , Liang Cheng , Xijie Liu , Yuandong Hu , Xinhe Xu , Zhihua Liu , Lipeng Zhang , Wei Wu , Shulong Wang , Yu Shen , Gen Li , Yin Wang , Sheng Zhao , Chonglong Li , Jia Tang , Honghao Yu
发明人： Dengming Xiao , Liang Cheng , Xijie Liu , Yuandong Hu , Xinhe Xu , Zhihua Liu , Lipeng Zhang , Wei Wu , Shulong Wang , Yu Shen , Gen Li , Yin Wang , Sheng Zhao , Chonglong Li , Jia Tang , Honghao Yu
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D401/12 , C07D413/12 , C07D417/12 , C07D493/12
摘要： The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
摘要翻译：本发明涉及一种新型的作为FAK和/或Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，其制备方法和组合物以及该化合物用于抑制FAK和/或Pyk2的方法和用于治疗FAK和/或Pyk2介导的病症或疾病的方法。

3. 发明授权

US09127655B2 Liquid nitrogen pump equipment load testing and experimenting apparatus and testing and experimenting method thereof 有权
标题翻译：液氮泵设备负荷试验及试验装置及其试验及试验方法
公开(公告)号：US09127655B2
公开(公告)日：2015-09-08
申请号：US13879111
申请日：2011-09-28
申请人： Shulong Wang , Xianying Tan , Xiaolin Wang , Hongguang Zhang , Yongqing Shi , Fang Gu
发明人： Shulong Wang , Xianying Tan , Xiaolin Wang , Hongguang Zhang , Yongqing Shi , Fang Gu
IPC分类号： E03B5/00 , F04B7/02 , F04B15/08 , F04B51/00
CPC分类号： F04B7/02 , F04B15/08 , F04B51/00 , F04B2015/0824
摘要： The disclosure relates to liquid nitrogen pump equipment load testing and experimenting apparatus, and testing and experimenting method thereof, used for oil-gas fields or coalbed methane nitrogen foam fracturing equipment testing. A hydraulic damping apparatus unit and a pressure regulation unit are provided; the hydro-mechanical damping apparatus unit comprises a water tank, a pump unit apparatus, and a pipe manifold system connected in sequence.
摘要翻译：本公开涉及用于油气田或煤层气氮气泡沫压裂设备试验的液氮泵设备负荷试验和试验装置及其试验和试验方法。提供液压阻尼装置单元和压力调节单元; 水力机械阻尼装置单元包括依次连接的水箱，泵单元装置和管道歧管系统。

4. 发明申请

US20130195690A1 LIQUID NITROGEN PUMP EQUIPMENT LOAD TESTING AND EXPERIMENTING APPARATUS AND TESTING AND EXPERIMENTING METHOD THEREOF 有权
标题翻译：液氮泵设备负荷试验及实验装置及其测试方法
公开(公告)号：US20130195690A1
公开(公告)日：2013-08-01
申请号：US13879111
申请日：2011-09-28
申请人： Shulong Wang , Xianying Tan , Xiaolin Wang , Hongguang Zhang , Yongqing Shi , Fang Gu
发明人： Shulong Wang , Xianying Tan , Xiaolin Wang , Hongguang Zhang , Yongqing Shi , Fang Gu
IPC分类号： F04B7/02
CPC分类号： F04B7/02 , F04B15/08 , F04B51/00 , F04B2015/0824
摘要： The disclosure relates to liquid nitrogen pump equipment load testing and experimenting apparatus, and testing and experimenting method thereof, used for oil-gas fields or coalbed methane nitrogen foam fracturing equipment testing. A hydraulic damping apparatus unit and a pressure regulation unit are provided; the hydro-mechanical damping apparatus unit comprises a water tank, a pump unit apparatus, and a pipe manifold system connected in sequence.
摘要翻译：本公开涉及用于油气田或煤层气氮气泡沫压裂设备试验的液氮泵设备负荷试验和试验装置及其试验和试验方法。提供液压阻尼装置单元和压力调节单元; 水力机械阻尼装置单元包括依次连接的水箱，泵单元装置和管道歧管系统。

5. 发明申请

US20070117992A1 Crystalline citalopram diol intermediate alkali 有权
标题翻译：结晶西酞普兰二醇中间体碱
公开(公告)号：US20070117992A1
公开(公告)日：2007-05-24
申请号：US10583360
申请日：2004-12-06
申请人： Runan Mei , Dianwu Guo , Shulong Wang
发明人： Runan Mei , Dianwu Guo , Shulong Wang
IPC分类号： C07D307/81
CPC分类号： C07D307/87 , C07C255/53
摘要： The present invention relates to the diol intermediate of citalopram useful for treatment of depression, that is to say, the crystal of free alkali of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described alkali;the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be signally improved, and the production cost of the medicinal material can be decreased.
摘要翻译：本发明涉及可用于治疗抑郁症的西酞普兰的二醇中间体，也就是3-羟甲基-4- [1-（4-氟苯基）-1-羟基-4-（二甲基氨基）]丁基苄腈及其结晶方法。本发明公开了通过所述碱的结晶制备纯西酞普兰及其纯化盐的方法，西酞普兰二醇中间体的光学拆分方法，上述晶体制备S-西酞普兰及其纯化盐的方法。本发明还公开了制备西酞普兰及其纯化盐S-西酞普兰及其纯化盐的方法及其药物制剂。采用本发明的方法，可以显着提高产品的质量和产量，降低药材的生产成本。

6. 发明授权

US09499530B2 Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament 有权
标题翻译：喹唑啉衍生物，具有该衍生物的组合物，以及该衍生物在制备药物中的用途
公开(公告)号：US09499530B2
公开(公告)日：2016-11-22
申请号：US14234326
申请日：2012-07-21
申请人： Shulong Wang , Jian Cai , Qiufu Ge , Dianwu Guo , Lan Yang , Binnan Huang , Zhenhua Liu , Zhonghua Peng , Ximing Shen , Feiyu Feng
发明人： Shulong Wang , Jian Cai , Qiufu Ge , Dianwu Guo , Lan Yang , Binnan Huang , Zhenhua Liu , Zhonghua Peng , Ximing Shen , Feiyu Feng
IPC分类号： C07D417/04 , C07D405/14 , C07D405/04 , C07D403/14
CPC分类号： C07D417/04 , C07D403/14 , C07D405/04 , C07D405/14
摘要： A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.
摘要翻译：提供了一类具有新颖结构的喹唑啉衍生物或其药学上可接受的盐或溶剂合物; 同时，还提供了包含药学上有效量的所述喹唑啉衍生物或其药学上可接受的盐或溶剂合物以及药学上可接受的赋形剂或添加剂的药物组合物。通过修饰和转化喹唑啉和筛选转化的化合物对酪氨酸激酶抑制的活性，已经发现大多数化合物具有对EGFR，VEGFR-2，c-erbB-2，c- erbB-4，c-met，tie-2，PDGFR，c-src，lck，Zap70和fyn激酶。本发明设计合理，原料来源广泛，易于获得原料，操作简便，制备方法简单，反应条件温和，产品收率高，有利于工业规模生产。

7. 发明授权

US07435838B2 Crystalline citalopram diol intermediate alkali 有权
标题翻译：结晶西酞普兰二醇中间体碱
公开(公告)号：US07435838B2
公开(公告)日：2008-10-14
申请号：US10583360
申请日：2004-12-06
申请人： Runan Mei , Dianwu Guo , Shulong Wang
发明人： Runan Mei , Dianwu Guo , Shulong Wang
IPC分类号： C07D307/78 , C07D307/87 , C07D307/93
CPC分类号： C07D307/87 , C07C255/53
摘要： The present invention relates to the diol intermediate of citalopram useful for treatment of depression, which is the crystal of free base of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)]butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described base; the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be significantly improved, and the production cost of the medicinal material can be reduced.
摘要翻译：本发明涉及可用于治疗抑郁症的西酞普兰的二醇中间体，其是3-羟甲基-4- [1-（4-氟苯基）-1-羟基-4-（二甲基氨基）]丁基苄腈的游离碱的晶体及其结晶方法。本发明公开了通过所述碱的结晶制备纯西酞普兰及其纯化盐的方法; 西酞普兰二元醇中间体的光学拆分方法，上述晶体制备S-西酞普兰及其纯化盐的方法。本发明还公开了制备西酞普兰及其纯化盐S-西酞普兰及其纯化盐的方法及其药物制剂。采用本发明的方法可以显着提高产品的质量和产量，降低药材的生产成本。

8. 发明申请

US20070191360A1 Curcumol derivatives, the compositions containing the said derivatives, and the use of the same in the manufacture of medicaments 失效
标题翻译：姜黄衍生物，含有所述衍生物的组合物及其在制备药物中的用途
公开(公告)号：US20070191360A1
公开(公告)日：2007-08-16
申请号：US11568770
申请日：2005-05-26
申请人： Shulong Wang , Dianwu Guo , Zhaoke Meng
发明人： Shulong Wang , Dianwu Guo , Zhaoke Meng
IPC分类号： A61K31/5377 , A61K31/506 , A61K31/496 , A61K31/452 , A61K31/353
CPC分类号： C07D493/10 , C07D493/08 , C07D493/20
摘要： The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ═CHR2, —CH2R2, ═O, —OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmeceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.
摘要翻译：本发明提供下式（I）的姜黄素衍生物或其药学上可接受的盐：其中Y选自-CHR 2，-CH 2， R 2，-O，-OH或-OR 1; R 1选自H，R，RCO或HO 3 并且R选自H; 饱和或不饱和直链C 1-10烃基等; R 2选自F; Cl; Br; 一世; H; -哦; -要么; -HSO 3等; 条件是R 1和R 2两者都不是H.本发明还提供了包含所述衍生物或其药学上可接受的盐的抗肿瘤或抗病毒药物组合物。本发明还提供了所述衍生物或其药学上可接受的盐在制备用于预防和/或治疗肿瘤或抗病毒药物的药物中的用途。

9. 发明申请

US20150080392A1 QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT 有权
标题翻译：喹啉衍生物，具有衍生物的组合物，以及衍生物在制备药物中的用途
公开(公告)号：US20150080392A1
公开(公告)日：2015-03-19
申请号：US14234326
申请日：2012-07-21
申请人： Shulong Wang , Jian Cai , Qiufu Ge , Dianwu Guo , Lan Yang , Binnan Huang , Zhenhua Liu , Zhonghua Peng , Ximing Shen , Feiyu Feng
发明人： Shulong Wang , Jian Cai , Qiufu Ge , Dianwu Guo , Lan Yang , Binnan Huang , Zhenhua Liu , Zhonghua Peng , Ximing Shen , Feiyu Feng
IPC分类号： C07D417/04 , C07D403/14 , C07D405/04
CPC分类号： C07D417/04 , C07D403/14 , C07D405/04 , C07D405/14
摘要： A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.
摘要翻译：提供了一类具有新颖结构的喹唑啉衍生物或其药学上可接受的盐或溶剂合物; 同时，还提供了包含药学上有效量的所述喹唑啉衍生物或其药学上可接受的盐或溶剂合物以及药学上可接受的赋形剂或添加剂的药物组合物。通过修饰和转化喹唑啉和筛选转化的化合物对酪氨酸激酶抑制的活性，已经发现大多数化合物具有对EGFR，VEGFR-2，c-erbB-2，c- erbB-4，c-met，tie-2，PDGFR，c-src，lck，Zap70和fyn激酶。本发明设计合理，原料来源广泛，易于获得原料，操作简便，制备方法简单，反应条件温和，产品收率高，有利于工业规模生产。

10. 发明授权

US07700584B2 Curcumol derivatives, the compositions containing the said derivatives, and the use of the same in the manufacture of medicaments 失效
标题翻译：姜黄衍生物，含有所述衍生物的组合物及其在制备药物中的用途
公开(公告)号：US07700584B2
公开(公告)日：2010-04-20
申请号：US11568770
申请日：2005-05-26
申请人： Shulong Wang , Dianwu Guo , Zhaoke Meng
发明人： Shulong Wang , Dianwu Guo , Zhaoke Meng
IPC分类号： A61K43/00 , A61K43/16 , C07D311/94 , C07D265/30 , C07D401/00
CPC分类号： C07D493/10 , C07D493/08 , C07D493/20
摘要： The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ═CHR2, —CH2R2, ═O, —OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmaceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.
摘要翻译：本发明提供下式（I）的姜黄素衍生物或其药学上可接受的盐：其中Y选自：CHR 2，-CH 2 R 2，= O，-OH或-OR 1; R 1选自H， R，RCO或HO3S; 并且R选自H; 饱和或不饱和直链C 1-10烃基等; R2选自F; Cl; Br; 一世; H; -哦; -要么; -HSO 3等; 条件是R1和R2都不为H.本发明还提供包含所述衍生物或其药学上可接受的盐的抗肿瘤或抗病毒药物组合物。本发明还提供了所述衍生物或其药学上可接受的盐在制备用于预防和/或治疗肿瘤或抗病毒药物的药物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式